* *



écrire à la sflm
écrire au webmestre

Dernière mise à jour 2018-11-23 

Carte des visites
réinitialisée après le congrès 2017

Articles scientifiques récents

    Ces articles sélectionnés ont été publiés au cours des 30 derniers jours.

    Vous trouverez ici le titre, la référence bibliographique, la date de publication, les auteurs, l'abstract, et un lien menant à la base de référencement où il est possible de consulter l'article entier, gratuit ou payant selon le cas.

  • Related Articles

    Facile synthesis of novel carbon-dots/hemin nanoplatforms for synergistic photo-thermal and photo-dynamic therapies.

    J Inorg Biochem. 2019 Feb 01;193:166-172

    Authors: Yang W, Wei B, Yang Z, Sheng L

    Due to the traditional therapies of cancer inducing huge pains to patients, the non-invasive photo-guided therapies are attracting massive attentions of researchers. Herein, the intelligent-designed carbon-dots/hemin nanoplatforms (HCDs NPs) were developed, owning high-authority photo-therapy for cancer. The fluorescence resonance energy transfer (FRET) effect enhanced the photo-thermal ability of HCDs NPs, endowing the synthesized nanoplatforms with photo-dynamic property simultaneously. Therefore, the obtained HCDs NPs could achieve synergetic photo-thermal and photo-dynamic therapies for cancer. Basing on the experimental results, the prepared HCDs NPs could induce the temperature enhancement high to ca 26 °C under laser irradiation, also with the outstanding photo-dynamic efficacy. More than 90% of cancer cells die after 10 min laser treatment. Thus, the dual-modal photo-therapeutic HCDs NPs are promising and excellent nanomaterials for potential application in synergistic cancer therapy.

    PMID: 30772693 [PubMed - as supplied by publisher]

    Accès à la base de référencement pour cet article

  • Related Articles

    Current Treatment and Management of Infantile Hemangiomas.

    Surv Ophthalmol. 2019 Feb 14;:

    Authors: Satterfield KR, Chambers CB

    Infantile hemangiomas (IHs), otherwise known as infantile capillary hemangiomas, strawberry hemangiomas, or strawberry nevi, are non-malignant vascular tumors that commonly affect children. The natural disease course typically involves growth for up to a year followed by regression without treatment over a period of years, with no cosmetic or functional sequelae. Less commonly, however, IHs can become a threat to vision or even life depending on location and size of the lesion. Additionally, IHs, particularly those involving the face, may be disfiguring and result in lifelong sequelae. β-blockers have become a mainstay of therapy given their relatively low-risk profile and efficacy. Other treatment modalities previously described in the literature include corticosteroids (both intralesional and systemic), imiquimod, vincristine, bleomycin A5, and interferon α. More recently, ACE-inhibitors such as captopril have been used. Laser therapy and, less commonly, surgical excision are also available treatment options. We review current recommended management and treatment of capillary hemangiomas and discuss the benefits and risks of all previously reported treatment modalities.

    PMID: 30772366 [PubMed - as supplied by publisher]

    Accès à la base de référencement pour cet article

  • Icon for Springer Related Articles

    Do electrical current and laser therapies improve bone remodeling during an orthodontic treatment with corticotomy?

    Clin Oral Investig. 2019 Feb 15;:

    Authors: Zaniboni E, Bagne L, Camargo T, do Amaral MEC, Felonato M, de Andrade TAM, Dos Santos GMT, Caetano GF, Esquisatto MAM, Santamaria M, Mendonça FAS

    OBJECTIVES: Evaluate the bone remodeling during orthodontic movement with corticotomy when submitted to low-intensity electrical stimulation application (microcurrent-MC) and low-level laser therapy (LLLT).
    MATERIAL AND METHODS: One hundred and fifty Wistar rats were divided into the following 5 groups: (C) submitted to tooth movement; (Cort) tooth movement/corticotomy; (Cort-L) tooth movement/corticotomy/laser AsGaAl 808 nm (4.96J/50s); (Cort-Mc) tooth movement/corticotomy/microcurrent (10 μA/5 min); (Cort-L-Mc) tooth movement/corticotomy and laser/microcurrent alternated. Inflammation, angiogenesis, and osteogenesis were evaluated in the periodontal ligament (PDL) and alveolar bone on the 7th, 14th, and 21st days of orthodontic movement.
    RESULTS: The quantification of inflammatory infiltrate, angiogenesis and expression of TGF-β1, VEGF, and collagen type I were favorably modulated by the application of therapies such as low-level laser therapy (LLLT), MC, or both combined. However, electrical stimulation increased fibroblasts, osteoclasts and RANK numbers, birefringent collagen fiber organization, and BMP-7 and IL-6 expression.
    CONCLUSIONS: Low-level laser therapy (LLLT) and MC application both improved the process of bone remodeling during orthodontic treatment with corticotomy. Still, electrical current therapy promoted a more effective tooth displacement but presented expected root resorption similar to all experimental treatments.
    CLINICAL RELEVANCE: It is important to know the effects of minimally invasive therapies on cellular and molecular elements involved in the bone remodeling of orthodontic treatment associated with corticotomy surgery, in order to reduce the adverse effects in the use of this technique and to establish a safer clinical routine.

    PMID: 30771000 [PubMed - as supplied by publisher]

    Accès à la base de référencement pour cet article

  • Icon for Wiley Related Articles

    Efficacy of fractional CO2 laser with intralesional steroid compared with intralesional steroid alone in the treatment of keloids and hypertrophic scars.

    J Cosmet Dermatol. 2019 Feb 15;:

    Authors: Alexander S, Girisha BS, Sripathi H, Noronha TM, Alva AC

    BACKGROUND AND OBJECTIVE: Keloids and hypertrophic scars (HTS) are abnormal fibrous reactions that persist for prolonged periods, rarely regress without treatment and recur after excision. Many modalities of treatment have been advocated but the success rates of these have been variable. The present study is an attempt to evaluate and compare the efficacy of combination of fractional CO2 laser (FCL) and intralesional steroid (ILS) against ILS alone in the treatment of keloids and HTS.
    METHODS: Patients with keloids or HTS were divided into two groups of 25 each receiving four sessions of therapy. Group 1 (FCL + ILS) received combination of FCL and intralesional triamcinolone acetonide (TAC) 10 mg/mL. Group 2 (ILS only) received intralesional TAC 10 mg/mL alone. Pretreatment measurements and photographs were taken. Two unbiased qualified dermatologists made independent evaluation of the photographs using modified Manchester quartile score (MQS). The patient's satisfaction to treatment was graded on a scale of 1-4. Statistical analysis was done using a statistical software.
    RESULTS: Statistically significant improvement was seen in height and length of the lesions. Overall appearance criteria of modified MQS showed an improvement of more than 50% in 43.3% of the lesions by the end of four sessions. Degree of hypertrophy showed more than 50% improvement in 40% of the lesions treated. Dyschromia showed more than 50% improvement in 33.4%. Texture showed the least improvement, with only 30% of lesions showing an improvement of more than 50%. The improvement of these parameters in ILS only group was significantly lower than the improvement seen in the FCL + ILS group.
    CONCLUSION: Combination therapy with FCL and ILS was superior in efficacy when compared to ILS alone, in the treatment of keloids and HTS.

    PMID: 30770627 [PubMed - as supplied by publisher]

    Accès à la base de référencement pour cet article

  • Icon for SLACK Incorporated. Related Articles

    Topical Aqueous Suppression and Closure of Idiopathic Full-Thickness Macular Holes.

    Ophthalmic Surg Lasers Imaging Retina. 2019 Feb 01;50(2):e38-e43

    Authors: Su D, Obeid A, Hsu J

    Hydration of retinal tissue has been proposed as a potential model of macular hole (MH) formation in addition to tractional forces of the vitreous and internal limiting membrane (ILM). Carbonic anhydrase inhibitors have previously been utilized in the treatment of cystoid macular edema in outer retinal diseases. There has been recent interest in the use of topical aqueous suppression as a potential medical therapy for MHs. In this case series, four eyes with small (< 300 μm) full-thickness MHs were treated with topical dorzolamide-timolol for 1 month. Two eyes achieved closure of the MH without surgical intervention, whereas the other two required pars plana vitrectomy with ILM peel. Future studies are required to investigate the role of topical aqueous suppression in the management of MHs. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e38-e43.].

    PMID: 30768228 [PubMed - in process]

    Accès à la base de référencement pour cet article

  • Icon for SLACK Incorporated. Related Articles

    Revascularization After Intravitreal Bevacizumab and Laser Therapy of Bilateral Retinal Vascular Occlusions in Incontinentia Pigmenti (Bloch-Sulzberger Syndrome).

    Ophthalmic Surg Lasers Imaging Retina. 2019 Feb 01;50(2):e33-e37

    Authors: Cernichiaro-Espinosa LA, Patel NA, Bauer MS, Negron CI, Fallas B, Pogrebniak A, Berrocal AM

    No consensus exists for the treatment of retinopathy in incontinentia pigmenti (IP). Vascular ischemia leads to tractional retinal detachments if untreated. Ultra-widefield fluorescein angiography (FA) is used to follow the vascular status of the retina. A 13-week-old female with IP presented with bilateral retinal vascular occlusions in both eyes. Ultra-widefield FA showed reperfusion after treatment with intravitreal bevacizumab (IVB) and angiography-guided laser to the avascular retina. Anti-vascular endothelial growth factor treatment reduces neovascularization and allows for growth of retinal vessels. IVB and FA-guided laser to the avascular retina is an option in IP. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e33-e37.].

    PMID: 30768227 [PubMed - in process]

    Accès à la base de référencement pour cet article

  • Icon for SLACK Incorporated. Related Articles

    Baseline Ocular Characteristics of Patients Undergoing Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.

    Ophthalmic Surg Lasers Imaging Retina. 2019 Feb 01;50(2):69-75

    Authors: Ansari WH, Han MM, Haq S, Conti FF, Silva FQ, Singh RP

    BACKGROUND AND OBJECTIVES: Patients with diabetic macular edema (DME) have variable anatomic and visual responses to anti-vascular endothelial growth (VEGF) treatments based on their presenting visual acuity (VA). The aim of study is to report the baseline ocular and imaging characteristics of patients presenting with DME who were treatment-naïve and who initiated anti-VEGF in routine clinical practice.
    PATIENTS AND METHODS: Single-center, cross-sectional study of 638 patients. Subjects were divided into two VA groups: Early Treatment Diabetic Retinopathy Study (ETDRS) less than 70 and ETDRS greater than 70 and ocular variables were compared between groups.
    RESULTS: Average central subfield thickness (CST) was 363.5 μm, cube volume was 11.7 mm3, and cube average thickness (CAT) was 326.1 μm. Additionally, 21.5% had subretinal fluid (SRF), and 50.5% had hard exudates on presentation. Eyes with ETDRS less than 70 had greater CAT (338.5 μm3 vs. 313.2 μm3; P < .001), greater cube volume (12.2 mm3 vs. 11.3 mm3; P < .001), greater CST (383.5 μm vs. 350.0 μm; P < .001), and SRF (25.5% vs. 17.3%; P = .012). Furthermore, 7.64% had glaucoma, 1.3% had dry age-related macular degeneration, 4.5% of patients were vitrectomized, and 28.7% were pseudophakic. Regarding diabetic stage, 37% had proliferative diabetic retinopathy (PDR) and 63% presented with nonproliferative diabetic retinopathy. Patients presenting with ETDRS less than 70 were more likely to have a history of vitrectomy (7.1% vs. 1.9%, P = .002) and presence of PDR (42.3% vs. 31.4%, P = .004).
    CONCLUSION: The results describe a population of patients from a routine clinical practice not entirely represented in clinical trials, with key differences in ocular characteristics seen between VA groups. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:69-75.].

    PMID: 30768213 [PubMed - in process]

    Accès à la base de référencement pour cet article

  • Icon for BioMed Central Related Articles

    Histologic findings associated with laser interstitial thermotherapy for glioblastoma multiforme.

    Diagn Pathol. 2019 Feb 15;14(1):19

    Authors: Elder JB, Huntoon K, Otero J, Kaya B, Hatef J, Eltobgy M, Lonser RR

    BACKGROUND: Laser-interstitial thermal therapy (LITT) has been supported by some authors as an ablative treatment of glioblastoma multiforme (GBM). Although the effects of LITT have been modeled in vivo, the histologic effects in a clinical circumstance have not been described. We analyzed tissue from a patient who underwent LITT as primary treatment for GBM.
    CASE PRESENTATION: A 62-year-old male was diagnosed with a left temporal GBM and underwent LITT at an outside institution. Despite corticosteroid therapy, the patient was referred with increasing headache and acalculia associated with progressive peritumoral edema two weeks after LITT procedure. En bloc resection of the enhancing lesion and adjacent temporal lobe was performed with steroid-independent symptom resolution (follow-up, > 2 years). Histologic analysis revealed three distinct histologic zones concentrically radiating from the center of the treatment site. An acellular central region of necrosis (Zone 1) was surrounded by a rim of granulation tissue with macrophages (CD68) (Zone 2; mean thickness, 1.3 ± 0.3 mm [±S.D.]). Viable tumor cells (identified by Ki-67, p53 and Olig2 immunohistochemistry) were found (Zone 3) immediately adjacent to granulation tissue. The histologic volume of thermal tissue ablation/granulation was consistent with preoperative (pre-resection) magnetic resonance (MR)-imaging.
    CONCLUSION: These findings are the first in vivo in humans to reveal that LITT causes a defined pattern of tissue necrosis, concentric destruction of tumor and tissue with viable tumor cells just beyond the zones of central necrosis and granulation. Furthermore, MR-imaging appears to be an accurate surrogate of tissue/tumor ablation in the early period (2 weeks) post-LITT treatment. Surgery is an effective strategy for patients with post-LITT swelling which does not respond to steroids.

    PMID: 30767775 [PubMed - in process]

    Accès à la base de référencement pour cet article

  • Related Articles

    Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.

    OMICS. 2019 Feb;23(2):119-130

    Authors: Cao F, Li X, Yang Y, Fang H, Qu H, Chang N, Ma Q, Cao W, Zhou J, Wang W

    The introduction of arsenic trioxide (ATO) in treatment of acute promyelocytic leukemia (APL) has resulted in high clinical complete remission (CR) rates over 90%. On the contrary, the risk for early death (ED) in APL patients treated with ATO continues to have a negative impact for optimization of APL therapeutics. There is an urgent need for precision medicine and biomarkers in clinical monitoring of ATO toxicity in APL, and ED in particular. This retrospective case series cohort proteomics study was conducted as a hypothesis generation effort and provides here several potential molecular leads on serum peptides expressed at different times after treatment with ATO in patients with APL. In 12 patients with a de novo APL diagnosis, and treated with single-agent ATO as frontline remission induction therapy, serum peptides were fractionated by weak cation exchange magnetic beads and analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Ten peptides (m/z 2075.5, 2084.2, 2203.0, 2265.2, 2872.8, 2916.6, 3145.2, 3153.4, 3953.4, and 3964.8) were significantly downregulated in serum after ATO treatment. Among them, four peptides were identified as (1) Immunoglobulin heavy chain V-III region BUT, (2) RRP15-like protein, (3) filaggrin, and (4) protein SON isoform F. To the best of our knowledge, this is the first clinical oncology proteomic biomarker study with a view to future rational therapeutic monitoring of patients with APL in the course of single-agent ATO treatment and hematological CR.

    PMID: 30767729 [PubMed - in process]

    Accès à la base de référencement pour cet article

  • Icon for Wiley Related Articles

    Nanogold Flower-Inspired Nanoarchitectonics Enables Enhanced Light-to-Heat Conversion Ability for Rapid and Targeted Chemo-Photothermal Therapy of a Tumor.

    Adv Healthc Mater. 2019 Feb 15;:e1801300

    Authors: Liu J, Zhai F, Zhou H, Yang W, Zhang S

    Chemo-photothermal therapy has become a promising tool for clinical noninvasive tumor therapy, which is able to efficiently avoid drug resistance and other side effects from chemical anticarcinogenic drugs. The ability to selectively fast-heat tumor tissues over surrounding compartments is of fundamental importance and makes effective treatment of tumor margins and complex tumor geometries. Currently existing chemo-photothermal methods mainly show slow light-to-heat conversion with increased temperature up to around 45-57 °C for 5-20 min or a longer time in vitro under regular near-infrared laser irradiation, and during tumor therapy, worse performance in temperature changes are obtained due to the much longer penetration distance in vivo. Herein, nanoarchitectonics with excellent chemo-photothermal performance are first proposed for tumors via in situ decoration of nanogold flowers on graphene oxide surface with further modification of the aptamer molecule. Even with simple synthesis processes, these nanoarchitectonics demonstrate impressive increased temperatures up to 85 °C in just 2 min under 808 nm laser irradiation with regular power density. Due to the fast light-to-heat conversion ability and specific binding effect between the aptamer and tumor cells, the designed nanocarrier shows a rapid and target therapy system with a targeted chemo-photothermal tumor treatment.

    PMID: 30767418 [PubMed - as supplied by publisher]

    Accès à la base de référencement pour cet article

  • Icon for Wiley Related Articles

    Current management of glaucoma.

    Med J Aust. 2019 Feb 14;:

    Authors: Lusthaus J, Goldberg I

    Glaucoma is an irreversible progressive optic neuropathy, for which the major proven treatment is to lower the intraocular pressure (IOP). Five groups of IOP-lowering eye drops have varying mechanisms of action. Some drops, such as β-blockers and α-2 agonists, have potentially serious systemic side effects. Acetazolamide is the only available oral agent; it is effective at lowering IOP, but significant side effects relegate its use usually to refractory glaucoma. Two new eye drops, netarsudil and latanoprostene bunod, have recently been approved by the United States Food and Drug Administration. Both have novel IOP-lowering mechanisms and target the conventional aqueous outflow system. Selective laser trabeculoplasty is a gentle treatment that enhances conventional aqueous outflow. It may be used as an initial treatment, as a substitute for eye drops, or to delay glaucoma drainage surgery. Recent advancements in glaucoma surgery have seen an influx of minimally invasive glaucoma surgery devices, which are being used more frequently and earlier on in the treatment paradigm. As limited long term data are available, trabeculectomy remains the gold standard IOP-lowering procedure. Improvements in drug delivery are on the horizon. Drug-eluting devices and implants are able to deliver the drug closer to the receptors for an extended period of time. This will improve treatment adherence and efficacy, which are major limitations with current medical therapy.

    PMID: 30767238 [PubMed - as supplied by publisher]

    Accès à la base de référencement pour cet article

  • Icon for Nature Publishing Group Related Articles

    Nuclear nanomedicine using Si nanoparticles as safe and effective carriers of 188Re radionuclide for cancer therapy.

    Sci Rep. 2019 Feb 14;9(1):2017

    Authors: Petriev VM, Tischenko VK, Mikhailovskaya AA, Popov AA, Tselikov G, Zelepukin I, Deyev SM, Kaprin AD, Ivanov S, Timoshenko VY, Prasad PN, Zavestovskaya IN, Kabashin AV

    Nuclear nanomedicine, with its targeting ability and heavily loading capacity, along with its enhanced retention to avoid rapid clearance as faced with molecular radiopharmaceuticals, provides unique opportunities to treat tumors and metastasis. Despite these promises, this field has seen limited activities, primarily because of a lack of suitable nanocarriers, which are safe, excretable and have favorable pharmacokinetics to efficiently deliver and retain radionuclides in a tumor. Here, we introduce biodegradable laser-synthesized Si nanoparticles having round shape, controllable low-dispersion size, and being free of any toxic impurities, as highly suitable carriers of therapeutic 188Re radionuclide. The conjugation of the polyethylene glycol-coated Si nanoparticles with radioactive 188Re takes merely 1 hour, compared to its half-life of 17 hours. When intravenously administered in a Wistar rat model, the conjugates demonstrate free circulation in the blood stream to reach all organs and target tumors, which is radically in contrast with that of the 188Re salt that mostly accumulates in the thyroid gland. We also show that the nanoparticles ensure excellent retention of 188Re in tumor, not possible with the salt, which enables one to maximize the therapeutic effect, as well as exhibit a complete time-delayed conjugate bioelimination. Finally, our tests on rat survival demonstrate excellent therapeutic effect (72% survival compared to 0% of the control group). Combined with a series of imaging and therapeutic functionalities based on unique intrinsic properties of Si nanoparticles, the proposed biodegradable complex promises a major advancement in nuclear nanomedicine.

    PMID: 30765778 [PubMed - in process]

    Accès à la base de référencement pour cet article

  • Icon for Elsevier Science Related Articles

    Sialendoscopy plus laser lithotripsy in sialolithiasis of the submandibular gland in 64 patients: A simple and safe procedure.

    Auris Nasus Larynx. 2019 Feb 11;:

    Authors: Guenzel T, Hoch S, Heinze N, Wilhelm T, Gueldner C, Franzen A, Coordes A, Lieder A, Wiegand S

    OBJECTIVE: To demonstrate the safety and efficiency of holmium laser-assisted lithotripsy during sialendoscopy of the submandibular gland using a retrospective, interventional consecutive case series.
    METHODS: We performed 374 sialendoscopies between 2008 and 2015 and evaluated all patients regarding clinical symptoms, clinical findings, therapy and outcome. We performed 109 procedures of holmium laser-assisted lithotripsy in 64 patients whose sialoliths measured 5 mm or more in diameter. In addition to retrospective case note reviews, we performed telephone interviews of all patients in January 2017.
    RESULTS: We performed 374 consecutive submandibular gland sialendoscopy procedures in 276 patients between 2008 to 2015. Sialolithiasis had either previously been diagnosed, or symptoms highly suggestive of sialolithiasis of the submandibular gland presented in 197 patients. Holmium laser-assisted Laser lithotripsy was performed in 109 cases (64.9%). Smaller mobile concrement was removed directly either by forceps or wire basket, or following marsupialisation of the submandibular duct. This was the case in 88 patients (29.1%). Three patients (0.8%) required surgical removal of the submandibular gland due to early abscess. The majority of patients (n = 374 procedures; 90.1%) remained symptom-free after two or more years following intervention. In the remaining procedures (n = 37 procedures; 9.9%), patients reported discreet postprandial problems but did not seek medical attention. In total, we managed to preserve the submandibular gland and avoid open surgery in 99% of patients through endoscopic management of submandibular concrement and duct stenosis.
    CONCLUSION: Holmium laser-assisted lithotripsy is a simple, safe, and effective procedure for treating patients with sialolithiasis of the submandibular gland. Removal of the gland is rarely required, and removing the gland without prior sialendoscopy is no longer recommended. It should be offered to all patients with submandibular gland sialolithiasis, or such patients should be referred to the appropriate centre for sialendoscopy before submandibulectomy is considered.

    PMID: 30765274 [PubMed - as supplied by publisher]

    Accès à la base de référencement pour cet article

  • Icon for BioMed Central Icon for PubMed Central Related Articles

    Comparison of visual quality after EVO-ICL implantation and SMILE to select the appropriate surgical method for high myopia.

    BMC Ophthalmol. 2019 Feb 08;19(1):21

    Authors: Qin Q, Bao L, Yang L, He Z, Huang Z

    BACKGROUND: This study sought to compare the visual quality between intraocular collamer lens (EVO-ICL) implantation and small-incision lenticule extraction (SMILE) and determine the appropriate surgical method to treat patients with high myopia (- 6.25 to - 10 D).
    METHODS: A total of 48 eyes underwent EVO-ICL implantation and another 48 eyes underwent SMILE. The uncorrected distance visual acuity (UDVA), best-corrected distance visual acuity (BCVA) and equivalent spherical degree were compared across the SMILE (- 6.25 to - 10 D) and EVO-ICL (- 6.25 to - 10 D) implantation groups. Preoperative and postoperative visual quality parameters were compared between and within groups.
    RESULTS: The OQAS II values (OV 100%) one week and one month after surgery and the modulation transfer function (MTF), OV 20% and OV 9% values one week after surgery in the SMILE group were lower than the respective preoperative values. The objective scatter index (OSI) value increased one week as well as one month after surgery compared with the preoperative values. The MTF cut-off value of the SMILE group was lower than that of the EVO-ICL implantation group three months after surgery.
    CONCLUSIONS: For patients with high myopia, the postoperative visual quality of EVO- ICL implantation was slightly better than that of SMILE.

    PMID: 30732575 [PubMed - indexed for MEDLINE]

    Accès à la base de référencement pour cet article

  • Icon for Wolters Kluwer Related Articles

    Photobiomodulation with simultaneous use of red and infrared light emitting diodes in the treatment of temporomandibular disorder: study protocol for a randomized, controlled and double-blind clinical trial.

    Medicine (Baltimore). 2019 Feb;98(6):e14391

    Authors: Sousa DFM, Gonçalves MLL, Politti F, Lovisetto RDP, Fernandes KPS, Bussadori SK, Mesquita-Ferrari RA

    INTRODUCTION: Temporomandibular disorder (TMD) is considered the main cause of orofacial pain of non-dental origin, and a public health problem. The symptomatology is muscular and/or articular pain, restriction of the mandibular range of motion, and changes in the mandibular movement pattern. Due to its complexity there are already treatments using various forms of therapy. Photobiomodulation using light sources, such as low-level laser or light emitting diodes (LED), with different wavelengths, in a single or combined form, allows one more therapeutic resource to be explored. The objective of this study is to evaluate the effects of photobiomodulation with the simultaneous use of red and infrared LEDs, on pain, range of mandibular movements, and on the electrical activity of masticatory muscles in individuals with TMD.
    METHODS: A randomized, controlled, double-blind clinical trial is proposed, which will involve 33 individuals (n = 11 per group) of both sexes, ages 18 to 45 years in 3 groups: LED group; placebo group; and control group, submitted to 6 non-consecutive sessions of photobiomodulation totaling 2 weeks of treatment. The Research Diagnostic Criteria for Temporomandibular Disorders-RDC/TMD will be used to assess and determine the participants' TMD. The pain will be assessed using the Visual Analog Scale - VAS, the mandibular range of motion will be determined with the aid of a digital caliper, and the electrical activity of the masticatory muscles will be verified by electromyography. A mixed plate of 18 red LEDs-660 nm and 18 infrared LEDs-850 nm with power of 3.5 mW per LED, 4.45 mW/cm, radiant exposure of 5.35 J/cm, will be used for photobiomodulation. The irradiated area will be 14.13 cm, and energy of 75.6 J, in the TMJ region and in the bilateral masseter and temporal muscles. Participants from all groups will be reassessed after the first therapeutic intervention, and at the end of treatment.
    DISCUSSION: We expect the use of photobiomodulation with LEDs, infra and red, to reduce pain, improve temporomandibular joint function in patients with TMD, and thus improve the general conditions of the patient.

    PMID: 30732181 [PubMed - indexed for MEDLINE]

    Accès à la base de référencement pour cet article

  • Icon for BioMed Central Icon for PubMed Central Related Articles

    Combined phacoemulsification and viscocanalostomy with Ologen implant versus combined phacoemulsification and viscocanalostomy.

    BMC Ophthalmol. 2019 Feb 06;19(1):45

    Authors: Gad AAM, Abdulhalim BH, Lotfy A, Abdelrahman AM, Ahmed AS

    BACKGROUND: To study the efficacy of the biodegradable collagen implant Ologen® as an adjuvant in phaco-viscocanalostomy in patients with coexisting cataract and primary open angle glaucoma.
    METHODS: This prospective, interventional, randomized clinical study was done at Alpha Vision Center, Zagazig, Egypt. Patients with coexisting cataract and glaucoma were randomized to receive either phaco-viscocanalostomy (Phacovisco group) (39 eyes) or phaco-viscocanalostomy with Ologen® implant (OloPhacovisco group) (40 eyes). Follow-up period was 2 years. Nd:YAG laser goniopuncture was done in cases where the intraocular pressure (IOP) was elevated above 21 mmHg after discontinuation of corticosteroid eye drops at any follow-up visit.
    RESULTS: No significant operative or postoperative complications (other than failure) were encountered in either group. At 2 years follow-up, the mean IOP level was statistically significantly decreased in the OloPhacovisco group (p = 0.02) and complete success occurred in 23 eyes (59.0%) in the Phacovisco group and in 32 eyes (80.0%) in the OloPhacovisco group. There was a statistically significant higher success rate regarding complete success in patients that received Ologen® implant (p = 0.04).
    CONCLUSIONS: Ologen® implant improved the success rate of phaco-viscocanalostomy. Larger studies with longer follow-up periods may be required to confirm these findings.
    TRIAL REGISTRATION: This trial was retrospectively registered on 20/12/2018 under the number ( NCT03782051 ).

    PMID: 30727982 [PubMed - indexed for MEDLINE]

    Accès à la base de référencement pour cet article

    | Accueil | Actualités users | Applications | Congrès | Formation |
    | Inscriptions | Accès Membres | Industriels | Liens | Infos SFLM |